These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33704809)

  • 1. Approvals of type 2 diabetes drugs tested in cardiovascular outcome trials: A tripartite comparison.
    Shimazawa R; Ikeda M
    Br J Clin Pharmacol; 2021 Oct; 87(10):3938-3948. PubMed ID: 33704809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Cardiovascular Safety of DPP-4 Inhibitors.
    Subrahmanyan NA; Koshy RM; Jacob K; Pappachan JM
    Curr Drug Saf; 2021; 16(2):154-164. PubMed ID: 32819262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of Cardiovascular Outcomes Trials in Type 2 Diabetes for Primary Care.
    Unger J
    J Fam Pract; 2018 Jun; 67(6 suppl):S35-S40. PubMed ID: 29912999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System.
    Raschi E; Poluzzi E; Koci A; Antonazzo IC; Marchesini G; De Ponti F
    Nutr Metab Cardiovasc Dis; 2016 May; 26(5):380-6. PubMed ID: 27067162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
    Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
    Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials enrollment criteria to the US type 2 diabetes population.
    Wittbrodt ET; Eudicone JM; Bell KF; Enhoffer DM; Latham K; Green JB
    Am J Manag Care; 2018 Apr; 24(8 Suppl):S146-S155. PubMed ID: 29693361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
    Gourgari E; Wilhelm EE; Hassanzadeh H; Aroda VR; Shoulson I
    J Diabetes Complications; 2017 Dec; 31(12):1719-1727. PubMed ID: 28939018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationales of delay and difference in regulatory review by Japan, the USA and Europe among new drugs first approved in Japan.
    Tanaka M; Idei M; Sakaguchi H; Kato R; Sato D; Sawanobori K; Kawarasaki S; Hata T; Yoshizaki A; Nakamura M; Ikuma M
    Br J Clin Pharmacol; 2021 Aug; 87(8):3279-3291. PubMed ID: 33511674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review on cardiovascular effects of newer hypoglycaemic medications.
    Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
    Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Goldman JD
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.
    Baetta R; Corsini A
    Drugs; 2011 Jul; 71(11):1441-67. PubMed ID: 21812507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of cardiovascular outcome trials in type 2 diabetes.
    Cypryk K; Małecki P
    Endokrynol Pol; 2018; 69(4):. PubMed ID: 30209802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E; Cigolini M
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
    Viereck C; Boudes P
    Contemp Clin Trials; 2011 May; 32(3):324-32. PubMed ID: 21266202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transposition of cardiovascular outcome trial effects to the real-world population of patients with type 2 diabetes.
    Sciannameo V; Berchialla P; Avogaro A; Fadini GP;
    Cardiovasc Diabetol; 2021 May; 20(1):103. PubMed ID: 33971880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imbalance in glycemic control between the treatment and placebo groups in cardiovascular outcome trials in type 2 diabetes.
    Shimazawa R; Ikeda M
    J Pharm Policy Pract; 2019; 12():30. PubMed ID: 31832207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs.
    Alfayez OM; Al Yami MS; Alshibani M; Fallatah SB; Al Khushaym NM; Alsheikh R; Alkhatib N
    Prim Care Diabetes; 2019 Jun; 13(3):204-211. PubMed ID: 30713085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.